Condition: Systemic Sclerosis · Diffuse Sclerosis Systemic · Interstitial Lung Disease · Sponsor: Paul Szabolcs
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
This description comes directly from the study's public registry record.
Paul Szabolcs, MD · 412-692-6225 · paul.szabolcs@chp.edu
Shawna McIntyre, RN · 412-692-5552 · mcintyresm@upmc.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03630211